Eli Lilly’s Retevmo Becomes First RET Inhibitor to Succeed in Phase 3 Early-Stage Lung Cancer Trial

Eli Lilly and Company reported positive topline results from its Phase 3 LIBRETTO-432 clinical trial evaluating Retevmo (selpercatinib). The study tested the drug as an adjuvant therapy for patients with early-stage rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC).

The trial met its primary endpoint by demonstrating a statistically significant and clinically meaningful improvement in event-free survival compared to a placebo. This marks the first Phase 3 study to evaluate a selective RET inhibitor within this specific patient population.

While overall survival data remains immature, the current results trend favorably for Retevmo. Eli Lilly plans to present detailed findings at an upcoming medical conference and initiate discussions with global health authorities.